ABSTRACT
The hydroxynaphthoquinones, buparvaquone, 250C80 and 56W82, showed high activity in vitro against Leishmania donovani amastigotes in mouse peritoneal macrophages, with ED50 values of 0.05, 2.95 and 13.82 microM, respectively. Fourteen other hydroxynaphthoquinones were tested, of which only 566C80 and 608C86 showed significant activity against amastigotes. Buparvaquone, 250C80 and 56W82 were also highly-active against cultured promastigotes. In a BALB/c mouse model, treatment with 100 mg/kg/day for five days with buparvaquone, 250C80 and 566C80 (atovaquone) reduced liver amastigote numbers by 60%, 22% and 30.5%, respectively.
Subject(s)
Antiprotozoal Agents/pharmacology , Leishmania donovani/drug effects , Naphthoquinones/pharmacology , Animals , Drug Resistance , Macrophages/parasitology , Mice , Mice, Inbred BALB CABSTRACT
566C80 is a novel hydroxynaphthoquinone with broad-spectrum anti-parasitic properties. In vitro the compound was more potent against Plasmodium falciparum than any of the established anti-malarial drugs. It had good activity against the pathogen in Aotus monkeys and was also effective in rodents infected with various drug-resistant strains of P. yoelii and P. berghei. In mice the compound showed significant activity against Toxoplasma gondii. Evaluation of the metabolic stability of 566C80 to NADPH-mediated oxidative metabolism was made using microsome preparations from a number of species including man. Unlike other quinones examined, 566C80 was shown to be inert in these assays. In Phase 1 clinical studies up to 750mg of compound were given as a single oral dose to fasted healthy male adults. This was well tolerated and the plasma drug elimination half-life was approximately 70h. In these subjects a 450mg dose gave plasma concentrations of 0.1-0.3 micrograms/ml which were achieved 1 h post-dosing and remained so for at least 7 days. Volunteers ingesting food prior to drug administration had quinone plasma levels which were significantly higher. Phase II trials are now underway to assess 566C80 for use against malaria and opportunistic infections in AIDS patients.
Subject(s)
Acquired Immunodeficiency Syndrome/complications , Anti-Infective Agents/metabolism , Malaria, Falciparum/drug therapy , Naphthoquinones/metabolism , Opportunistic Infections/drug therapy , 4-Quinolones , Acquired Immunodeficiency Syndrome/drug therapy , Adult , Animals , Anti-Infective Agents/pharmacokinetics , Anti-Infective Agents/pharmacology , Antimalarials/metabolism , Antimalarials/pharmacokinetics , Antimalarials/pharmacology , Aotus trivirgatus , Atovaquone , Dogs , Humans , Malaria, Falciparum/metabolism , Male , Microsomes, Liver/metabolism , Middle Aged , NADP/metabolism , Naphthoquinones/pharmacokinetics , Naphthoquinones/pharmacology , Opportunistic Infections/etiology , Plasmodium/drug effects , Rats , Toxoplasma/drug effectsABSTRACT
A series of hydroxynaphthoquinones, all derivatives of the antitheilerial hydroxynaphthoquinone parvaquone (993C, Clexon; Wellcome) was tested for antitheilerial activity against Theileria parva (Muguga) in vitro. BW720C (buparvaquone) was 20 times more active than parvaquone. When tested in vivo BW720C cured all 13 cattle infected with T parva and all six infected with T annulata treated at a dose rate of 2.5 mg (kg bodyweight)-1 while parvaquone at 20 mg kg-1 cured nine of 10 cattle. All 16 untreated control cattle died of theileriosis.
Subject(s)
Antimalarials/pharmacology , Antiprotozoal Agents/pharmacology , Apicomplexa/drug effects , Naphthoquinones/pharmacology , Theileriasis/drug therapy , Animals , Antimalarials/therapeutic use , Antiprotozoal Agents/therapeutic use , Cattle , Chemical Phenomena , Chemistry , Kenya , Naphthoquinones/therapeutic use , Species SpecificityABSTRACT
Novel hydroxynaphthoquinones are reported with outstanding efficacy against Plasmodium, Eimeria and Theileria species. Biochemical evidence is presented for the selective toxicity of these compounds being due to inhibition of parasite respiratory systems.
Subject(s)
Antiprotozoal Agents/pharmacology , Apicomplexa/drug effects , Malaria/drug therapy , Naphthoquinones/pharmacology , Protozoan Infections/drug therapy , Animals , Antiprotozoal Agents/therapeutic use , Cattle , Chickens/parasitology , Coccidiosis/drug therapy , Eimeria/drug effects , Mice , Naphthoquinones/therapeutic use , Plasmodium berghei/drug effects , Plasmodium falciparum/drug effects , Theileriasis/drug therapy , Toxoplasma/drug effects , Toxoplasmosis, Animal/drug therapyABSTRACT
Novel hydroxynaphthoquinones have been shown to be potent and selective inhibitors of mitochondrial electron transport in the protozoan Eimeria tenella, inhibiting at concentrations of 10(-10) to 10(-11)M. The primary site of electron transport inhibition has been localized to the ubiquinol-cytochrome c reductase span of the respiratory chain, whereas a secondary site of inhibition occurs in the NADH- and succinate-ubiquinone reductase complexes. Inhibition at the primary site is selective for the E. tenella enzyme; inhibition at the secondary sites is comparable in both E. tenella and chick (Gallus gallus) liver mitochondria. Hydroxynaphthoquinone inhibition of chick liver succinate-cyto-chrome c reductase was fully reversible by addition of the exogenous ubiquinone-2 analogue, 6-decyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone; inhibition of the corresponding E. tenella enzyme was not reversed by this ubiquinone. E. tenella lines made resistant to the anticoccidial agents decoquinate or clopidol showed no cross-resistance to the hydroxynaphthoquinones, either at the level of electron transport or in vivo.
